Levomycetin (Tablets, Capsules, Solution, Drops, Powder) Instructions for Use
ATC Code
J01BA01 (Chloramphenicol)
Active Substance
Chloramphenicol (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Antibiotic of the chloramphenicol group
Pharmacotherapeutic Group
Antibiotic
Pharmacological Action
Broad-spectrum antibiotic. The mechanism of antimicrobial action is associated with the disruption of protein synthesis in the microbial cell at the stage of amino acid transfer by tRNA to ribosomes. It has a bacteriostatic effect.
It is active against gram-positive bacteria: Staphylococcus spp., Streptococcus spp.; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Haemophilus influenzae, Salmonella spp., Shigella spp., Klebsiella spp., Serratia spp., Yersinia spp., Proteus spp., Rickettsia spp.; also active against Spirochaetaceae, some large viruses.
Chloramphenicol is active against strains resistant to penicillin, streptomycin, and sulfonamides.
Microbial resistance to chloramphenicol develops relatively slowly.
Pharmacokinetics
After oral administration, it is rapidly and almost completely absorbed from the gastrointestinal tract. Absorption – 90%. Bioavailability – 80%. Plasma protein binding – 50-60%, in premature newborns – 32%. Time to reach Cmax after oral administration is 1-3 hours. Vd – 0.6-1 L/kg. Therapeutic concentration in the blood is maintained for 4-5 hours after administration.
It penetrates well into body fluids and tissues. Its highest concentrations are created in the liver and kidneys. Up to 30% of the administered dose is found in bile. Cmax in the cerebrospinal fluid (CSF) is determined 4-5 hours after a single oral dose and can reach 21-50% of the Cmax in plasma in the absence of meningeal inflammation and 45-89% in the presence of meningeal inflammation.
It crosses the placental barrier; concentrations in the fetal serum can be 30-80% of that in the maternal blood. It is excreted in breast milk. The main amount (90%) is metabolized in the liver. In the intestine, under the influence of intestinal bacteria, it is hydrolyzed to form inactive metabolites.
It is excreted by the kidneys within 24 hours – 90% (via glomerular filtration – 5-10% unchanged, via tubular secretion as inactive metabolites – 80%), through the intestine – 1-3%. T1/2 in adults is 1.5-3.5 hours, in case of impaired renal function – 3-11 hours. T1/2 in children from 3 to 16 years old – 3-6.5 hours. It is poorly removed during hemodialysis.
With intravaginal application, it is practically not absorbed and does not have a systemic effect.
Indications
Infectious and inflammatory diseases caused by susceptible microorganisms, including infections of the urinary and biliary tracts.
For external use: in the second phase of the wound process (absence of pus, necrotic tissue), long-term non-healing trophic ulcers, II-III degree burns.
For use in ophthalmology: bacterial eye infections caused by susceptible microorganisms.
For use in gynecology: vaginitis, cervicitis caused by susceptible microorganisms; prevention of purulent-inflammatory diseases in gynecology before invasive procedures (abortion, diathermocoagulation of the cervix, hysterosalpingography, before and after insertion of an intrauterine device).
ICD codes
| ICD-10 code | Indication |
| A04.6 | Enteritis due to Yersinia enterocolitica |
| A21 | Tularemia |
| A23 | Brucellosis |
| A28.2 | Extraintestinal yersiniosis |
| A28.8 | Other specified bacterial zoonoses, not elsewhere classified |
| A79 | Other rickettsioses |
| H01.0 | Blepharitis |
| H10.2 | Other acute conjunctivitis |
| H10.4 | Chronic conjunctivitis |
| H10.5 | Blepharoconjunctivitis |
| H15 | Diseases of sclera |
| H16 | Keratitis |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N76 | Other inflammatory diseases of vagina and vulva |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| O08.0 | Infection of genital tract and pelvic organs following abortion, ectopic and molar pregnancy |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| 1A05 | Intestinal infections due to Yersinia enterocolitica |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B94.Z | Tularemia, unspecified |
| 1B95 | Brucellosis |
| 1B9A | Extraintestinal yersiniosis |
| 1B9Z | Unspecified zoonotic bacterial diseases |
| 1C3Z | Rickettsioses, unspecified |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| 9A01.3 | Infectious blepharitis |
| 9A02.Z | Inflammatory disorders of eyelid, unspecified |
| 9A60.4 | Blepharoconjunctivitis |
| 9A60.Z | Conjunctivitis, unspecified |
| 9A71 | Infectious keratitis |
| 9A7Z | Diseases of the cornea, unspecified |
| 9B5Z | Disorders of sclera, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EB21 | Pyoderma gangrenosum |
| EF60 | Ischemic ulceration of the skin |
| EM0Z | Unspecified skin disorder |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| JA05.0 | Infection of genital tract or pelvic organs following abortion, ectopic or molar pregnancy |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QC05.Y | Other specified prophylactic measures |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution
For external use, apply to gauze swabs or directly to the affected area. A regular bandage is applied on top, possibly with parchment or compress paper. Dressings are changed depending on the indications every 1-3 days, sometimes every 4-5 days.
Tablets, Capsules
Take orally. Adults – 500 mg 3-4 times/day. Single doses for children under 3 years old – 15 mg/kg, 3-8 years old – 150-200 mg; over 8 years old – 200-400 mg; frequency of application – 3-4 times/day. The course of treatment is 7-10 days.
Drops
For topical use in ophthalmology every 1-4 hours. The treatment regimen is established individually as prescribed by the doctor.
Powder
Individual, depending on the indications, patient’s age, and the dosage form used.
Adverse Reactions
From the hematopoietic system reticulocytopenia, leukopenia, granulocytopenia, thrombocytopenia, erythrocytopenia; rarely – aplastic anemia, agranulocytosis.
From the digestive system nausea, vomiting, diarrhea, flatulence, dysbiosis.
From the nervous system psychomotor disorders, depression, confusion, peripheral neuritis, optic neuritis, visual and auditory hallucinations, decreased visual and hearing acuity, headache.
Allergic reactions skin rash, urticaria, angioedema.
Local reactions irritant effect (with external or topical application).
Other secondary fungal infection.
With intravaginal application allergic reactions, hematopoietic suppression, dyspepsia, dermatitis, suppression of normal microflora, secondary fungal infection, burning sensation during urination or frequent urination, itching, burning pain or hyperemia of the external genital mucosa, burning or irritation of the penis in the sexual partner, vaginal dysbiosis.
Contraindications
Hypersensitivity to chloramphenicol, bone marrow depression, acute intermittent porphyria, glucose-6-phosphate dehydrogenase deficiency, hepatic and/or renal failure, pregnancy, lactation period; for oral administration – children under 3 years of age and with body weight less than 20 kg; for use in gynecology – fungal diseases of the vagina, not used in girls before the onset of sexual activity; for use in ophthalmology – children under 4 weeks of age.
With caution
Children, patients who have previously received treatment with cytotoxic drugs or radiation therapy.
Use in Pregnancy and Lactation
Chloramphenicol is contraindicated for use during pregnancy and during the lactation (breastfeeding) period.
Use in Hepatic Impairment
Contraindicated in severe liver dysfunction.
Use in Renal Impairment
Contraindicated in severe renal impairment.
Pediatric Use
Use with caution in children.
Geriatric Use
Use with caution in elderly patients to avoid exacerbation of chronic diseases.
Special Precautions
Use with caution in patients who have previously received treatment with cytotoxic drugs or radiation therapy.
When taken simultaneously with alcohol, a disulfiram-like reaction may develop (skin hyperemia, tachycardia, nausea, vomiting, reflex cough, convulsions).
During treatment, systematic monitoring of the peripheral blood picture is necessary.
Uncontrolled prescription of chloramphenicol and its use for mild forms of infectious processes, especially in pediatric practice, is unacceptable.
Drug Interactions
With simultaneous use of chloramphenicol with oral hypoglycemic drugs, an enhancement of the hypoglycemic effect is noted due to the suppression of the metabolism of these drugs in the liver and an increase in their plasma concentration.
With simultaneous use with drugs that depress bone marrow hematopoiesis, an enhancement of the inhibitory effect on the bone marrow is noted.
With simultaneous use with erythromycin, clindamycin, lincomycin, a mutual weakening of the effect is noted due to the fact that Chloramphenicol can displace these drugs from the bound state or prevent their binding to the 50S subunit of bacterial ribosomes.
With simultaneous use with penicillins, Chloramphenicol counteracts the manifestation of the bactericidal action of penicillin.
Reduces the antibacterial effect of cephalosporins.
Chloramphenicol suppresses the cytochrome P450 enzyme system, therefore, with simultaneous use with phenobarbital, phenytoin, warfarin, a weakening of the metabolism of these drugs, a slowdown in their excretion, and an increase in their plasma concentration are noted.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Alcohol solution for external use 0.25%: 25 ml or 40 ml fl.
Marketing Authorization Holder
Vladivostok Pharmaceutical Factory, JSC (Russia)
Dosage Form
 |
Levomycetin solution In ethanol | Alcohol solution for external use 0.25%: 25 ml or 40 ml fl. |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 0.25% | 100 ml |
| Chloramphenicol | 250 mg |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 1%: 25 ml or 40 ml bottle.
Marketing Authorization Holder
Vladivostok Pharmaceutical Factory, JSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 1%: 25 ml or 40 ml bottle. |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 1% | 100 ml |
| Chloramphenicol | 1 g |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 3%: 25 ml or 40 ml bottle
Marketing Authorization Holder
Vladivostok Pharmaceutical Factory, JSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 3%: 25 ml or 40 ml bottle |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 3% | 100 ml |
| Chloramphenicol | 3 g |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 5%: 25 ml or 40 ml bottle
Marketing Authorization Holder
Vladivostok Pharmaceutical Factory, JSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 5%: 25 ml or 40 ml bottle |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 5% | 100 ml |
| Chloramphenicol | 5 g |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 3%: 25 ml or 40 ml bottle
Marketing Authorization Holder
Tver Pharmaceutical Factory, PJSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 3%: 25 ml or 40 ml bottle |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 3% | 100 ml |
| Chloramphenicol | 3 g |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 5%: 25 ml or 40 ml bottle
Marketing Authorization Holder
Tver Pharmaceutical Factory, PJSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 5%: 25 ml or 40 ml bottle |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 5% | 100 ml |
| Chloramphenicol | 5 g |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 1%: 25 ml or 40 ml bottle.
Marketing Authorization Holder
Tver Pharmaceutical Factory, PJSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 1%: 25 ml or 40 ml bottle. |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 1% | 100 ml |
| Chloramphenicol | 1 g |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 0.25%: 25 ml or 40 ml fl.
Marketing Authorization Holder
Tver Pharmaceutical Factory, PJSC (Russia)
Dosage Form
|
Levomycetin solution In ethanol | Alcohol solution for external use 0.25%: 25 ml or 40 ml fl. |
Dosage Form, Packaging, and Composition
| Solution for external use (alcohol) 0.25% | 100 ml |
| Chloramphenicol | 250 mg |
25 ml – dark glass bottles (1) – cardboard boxes.
40 ml – dark glass bottles (1) – cardboard boxes.
Alcohol solution for external use 0.25%: 25 ml bottle or dropper tube
Alcohol solution for external use 1%: 25 ml bottle or dropper tube
Alcohol solution for external use 3%: 25 ml bottle or dropper tube
Solution for external use, alcohol 5%: bottle or dropper tube 25 ml
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Forms
|
Levomycetin Renewal | Alcohol solution for external use 0.25%: 25 ml bottle or dropper tube |
| Alcohol solution for external use 1%: 25 ml bottle or dropper tube | ||
| Alcohol solution for external use 3%: 25 ml bottle or dropper tube | ||
| Solution for external use, alcohol 5%: bottle or dropper tube 25 ml |
Dosage Form, Packaging, and Composition
Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.
| 100 ml | |
| Chloramphenicol | 0.25 g |
Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.
25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.
Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.
| 100 ml | |
| Chloramphenicol | 1 g |
Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.
25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.
Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.
| 100 ml | |
| Chloramphenicol | 3 g |
Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.
25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.
Solution for external use, alcohol in the form of a transparent, colorless or yellowish liquid, with the smell of alcohol.
| 100 ml | |
| Chloramphenicol | 5 g |
Excipients : ethanol (ethyl alcohol) 70% – up to 100 ml.
25 ml – dark glass bottles (1) – cardboard packs.
25 ml – dropper tubes (1) – cardboard packs.
Film-coated tablets 250 mg: 10, 20, 30, or 50 pcs.
Film-coated tablets 500 mg: 10, 20, 30, or 50 pcs.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Forms
 |
Levomycetin Renewal | Film-coated tablets 250 mg: 10, 20, 30, or 50 pcs. |
| Film-coated tablets 500 mg: 10, 20, 30, or 50 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets blue in color, round, biconvex; the core on the cross-section is white or almost white.
| 1 tab. | |
| Chloramphenicol | 250 mg |
Excipients : microcrystalline cellulose 101, crospovidone, copovidone (Kollidon VA-64), povidone K30, calcium stearate, colloidal silicon dioxide (aerosil).
Shell composition: [polyvinyl alcohol (E1203), titanium dioxide, macrogol (polyethylene glycol), talc, aluminum lacquer based on indigo carmine dye (E132), yellow iron oxide (E172)] or [dry mix for film coating: polyvinyl alcohol (E1203), titanium dioxide, macrogol (polyethylene glycol), talc, aluminum lacquer based on indigo carmine dye (E132), yellow iron oxide (E172)].
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
Film-coated tablets blue in color, oval, biconvex, with a score; the core on the cross-section is white or almost white.
| 1 tab. | |
| Chloramphenicol | 500 mg |
Excipients : microcrystalline cellulose 101, crospovidone, copovidone (Kollidon VA-64), povidone K30, calcium stearate, colloidal silicon dioxide (aerosil).
Shell composition: [polyvinyl alcohol (E1203), titanium dioxide, macrogol (polyethylene glycol), talc, aluminum lacquer based on indigo carmine dye (E132), yellow iron oxide (E172)] or [dry mix for film coating: polyvinyl alcohol (E1203), titanium dioxide, macrogol (polyethylene glycol), talc, aluminum lacquer based on indigo carmine dye (E132), yellow iron oxide (E172)].
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
Eye drops 0.25%: dropper tube 1 ml or 2 ml 2 or 5 pcs., 1.5 ml 2 pcs., 5 ml or 10 ml 1 pc.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
|
Levomycetin Renewal | Eye drops 0.25%: dropper tube 1 ml or 2 ml 2 or 5 pcs., 1.5 ml 2 pcs., 5 ml or 10 ml 1 pc. |
Dosage Form, Packaging, and Composition
Eye drops in the form of a transparent, colorless or slightly yellowish liquid.
| 1 ml | |
| Chloramphenicol | 2.5 mg |
Excipients : boric acid – 18 mg, sodium tetraborate decahydrate – 3 mg, purified water – up to 1 ml.
1 ml – dropper tubes (2) – cardboard packs.
1 ml – dropper tubes (5) – cardboard packs.
1.5 ml – dropper tubes (2) – cardboard packs.
2 ml – dropper tubes (2) – cardboard packs.
2 ml – dropper tubes (5) – cardboard packs.
5 ml – dropper tubes (1) – cardboard packs.
10 ml – dropper tubes (1) – cardboard packs.
Powder for solution for intravenous and intramuscular administration 500 mg: vial 5 or 10 pcs.
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Form
|
Levomycetin sodium succinate | Powder for solution for intravenous and intramuscular administration 500 mg: vial 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for intravenous and intramuscular administration | 1 vial |
| Chloramphenicol sodium succinate | 500 mg |
Vials (5) – cardboard packs.
Vials (10) – cardboard packs.
Powder for solution for intravenous and intramuscular administration 1 g: fl. 5 or 10 pcs.
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Form
|
Levomycetin sodium succinate | Powder for solution for intravenous and intramuscular administration 1 g: fl. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for intravenous and intramuscular administration | 1 vial |
| Chloramphenicol sodium succinate | 1 g |
Vials (5) – cardboard packs.
Vials (10) – cardboard packs.
Powder for solution for intramuscular injection 500 mg: vial 1 pc. in a set with solvent
Marketing Authorization Holder
Biokhimik, JSC (Russia)
Dosage Form
|
Levomycetin succinate sodium | Powder for solution for intramuscular injection 500 mg: vial 1 pc. in a set with solvent |
Dosage Form, Packaging, and Composition
| Powder for solution for intramuscular administration | 1 vial |
| Chloramphenicol sodium succinate | 500 mg |
Solvent water for injections – 5 ml.
500 mg – vials (1) in a set with solvent (amp.) – cardboard packs.
Powder for solution for intramuscular administration 1 g: fl. 1 pc. with solvent in a set
Marketing Authorization Holder
Biokhimik, JSC (Russia)
Dosage Form
|
Levomycetin succinate sodium | Powder for solution for intramuscular administration 1 g: fl. 1 pc. with solvent in a set |
Dosage Form, Packaging, and Composition
| Powder for solution for intramuscular administration | 1 vial |
| Chloramphenicol sodium succinate | 1 g |
Solvent water for injections – 5 ml.
1 g – vials (1) in a set with solvent (amp.) – cardboard packs.
Powder for solution for injection 500 mg: fl. 5 or 10 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Form
|
Levomycetin succinate soluble | Powder for solution for injection 500 mg: fl. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for injection | 1 vial |
| Chloramphenicol sodium succinate | 500 mg |
Vials (10) – cardboard packs
Vials (5) – cardboard packs.
Powder for solution for injection 1 g: fl. 5 or 10 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Form
|
Levomycetin succinate soluble | Powder for solution for injection 1 g: fl. 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for injection | 1 vial |
| Chloramphenicol sodium succinate | 1 g |
Vials (10) – cardboard packs
Vials (5) – cardboard packs.
Tablets 500 mg: 10 pcs.
Marketing Authorization Holder
Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Levomycetin tablets | Tablets 500 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Chloramphenicol | 500 mg |
10 pcs. – non-cell contour packs.
10 pcs. – contour cell packs.
10 pcs. – contour cell packs (1) – cardboard packs.
Eye drops 0.25%: bottle or dropper bottle 5 ml or 10 ml
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Form
|
Levomycetin-AKOS | Eye drops 0.25%: bottle or dropper bottle 5 ml or 10 ml |
Dosage Form, Packaging, and Composition
Eye drops in the form of a transparent liquid with a slightly yellowish tint.
| 1 ml | |
| Chloramphenicol | 2.5 mg |
Excipients : boric acid, water for injections.
5 ml – bottles with a dosing nozzle (1) – cardboard packs.
5 ml – dropper bottles (1) – cardboard packs.
10 ml – bottles with a dosing nozzle (1) – cardboard packs.
10 ml – dropper bottles (1) – cardboard packs.
Eye drops 0.25%: dropper bottle 5 ml or 10 ml
Marketing Authorization Holder
Diafarm, JSC (Russia)
Dosage Form
|
Levomycetin-DIA | Eye drops 0.25%: dropper bottle 5 ml or 10 ml |
Dosage Form, Packaging, and Composition
| Eye drops 0.25% | 1 ml |
| Chloramphenicol | 2.5 mg |
Excipients: boric acid.
5 ml – polymer dropper bottles (1) – cardboard packs.
10 ml – polymer dropper bottles (1) – cardboard packs.
Capsules 250 mg: 10 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
|
Levomycetin-Ferein | Capsules 250 mg: 10 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Chloramphenicol | 250 mg |
10 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – dark glass jars (1) – cardboard packs.
Eye drops 0.25%: bottle 5 ml or 10 ml
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
|
Levomycetin-Ferein | Eye drops 0.25%: bottle 5 ml or 10 ml |
Dosage Form, Packaging, and Composition
| Eye drops 0.25% | 1 ml |
| Chloramphenicol | 2.5 mg |
5 ml – bottles (1) – cardboard packs.
10 ml – bottles (1) – cardboard packs.
Tablets 250 mg: 40 pcs.
Marketing Authorization Holder
Kyivmedpreparat PJSC (Ukraine)
Dosage Form
|
Levomycetin-KMP | Tablets 250 mg: 40 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Chloramphenicol | 250 mg |
10 pcs. – contour cell packs (4) – cardboard packs.
Tablets 500 mg: 40 pcs.
Marketing Authorization Holder
Kyivmedpreparat PJSC (Ukraine)
Dosage Form
|
Levomycetin-KMP | Tablets 500 mg: 40 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Chloramphenicol | 500 mg |
10 pcs. – contour cell packs (4) – cardboard packs.
Powder for solution for intramuscular injection 500 mg: vial 10 pcs.
Marketing Authorization Holder
Kyivmedpreparat PJSC (Ukraine)
Dosage Form
|
Levomycetin-KMP | Powder for solution for intramuscular injection 500 mg: vial 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intramuscular injection | 1 fl. |
| Chloramphenicol | 500 mg |
Vials (10) – cardboard packs.
Powder for solution for intramuscular injection 1 g: fl. 10 pcs.
Marketing Authorization Holder
Kyivmedpreparat PJSC (Ukraine)
Dosage Form
|
Levomycetin-KMP | Powder for solution for intramuscular injection 1 g: fl. 10 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intramuscular injection | 1 fl. |
| Chloramphenicol | 1 g |
Vials (10) – cardboard packs.
Capsules 250 mg: 10 or 20 pcs.
Marketing Authorization Holder
Patent-Pharm, JSC (Russia)
Manufactured By
Tyumen Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Levomycetin-LekT | Capsules 250 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard, gelatin No. 0, white in color, filled with granules of white or white with a faint yellowish-greenish tint.
| 1 caps. | |
| Chloramphenicol | 250 mg |
Excipients: potato starch – 34.5 mg, povidone K-30 – 2.9 mg, calcium stearate – 2.6 mg.
Capsule composition titanium dioxide – 2%, gelatin – up to 100%.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
Tablets 500 mg: 10, 20, 30, or 50 pcs.
Marketing Authorization Holder
Tyumen Chemical Pharmaceutical Plant, FSUE (Russia)
Dosage Form
|
Levomycetin-LekT | Tablets 500 mg: 10, 20, 30, or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Chloramphenicol | 500 mg |
10 pcs. – contour non-cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour non-cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour non-cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour non-cell packs (1).
Tablets 500 mg: 10, 20, 30, or 50 pcs.
Marketing Authorization Holder
Uralbiopharm, JSC (Russia)
Dosage Form
|
Levomycetin-UBF | Tablets 500 mg: 10, 20, 30, or 50 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Chloramphenicol | 500 mg |
10 pcs. – contour cell packs (1) – cardboard packs
10 pcs. – contour cell packs (2) – cardboard packs
10 pcs. – contour cell packs (3) – cardboard packs
10 pcs. – contour cell packs (5) – cardboard packs.
![Levomycetin [Tablets, Capsules, Solution, Drops, Powder] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Levomycetin [Tablets, Capsules, Solution, Drops, Powder] 2")